Mim8, is a novel, next-generation factor VIII mimetic human bispecific antibody developed by Novo Nordisk utilizing Genmab’s DuoBody® technology under an exclusive license agreement. Mim8 is a highly potent molecule bridging factor IXa (FIXa) and factor X (FX) in development for subcutaneous treatment of people with haemophilia A. 

Clinical studies
Mim8 is being investigated in a clinical study in healthy subjects and subjects with haemophilia A.